Articles tagged with Cancer Medication
Researchers at the University of Washington have developed a new nanocarrier system that can deliver chemotherapy drugs and imaging molecules to tumors, sparing healthy tissue from toxic side effects. The hybrid nanocarriers can also provide sustained imaging for months, enabling doctors to visualize tumors more effectively.
Researchers at Rockefeller University found genetic evidence of bacteria capable of producing compounds with potent effects as medicines in urban soil. The study identified a wide range of natural products with potential therapeutic applications, including antibiotics and antifungal agents.
Researchers found that AML patients with TP53 mutations respond to milder chemotherapy drug decitabine, achieving remission and median survival over a year. The study suggests using targeted therapy for younger patients carrying the mutation.
A study of Medicare beneficiaries with cancer found those without supplemental insurance faced the highest out-of-pocket costs. Hospitalizations were a primary reason for these costs, with some patients facing expenses exceeding 63% of their household income.
Scientists at UC San Diego School of Medicine discovered a key protein involved in protecting epithelial cells during stress, and found that the widely prescribed anti-diabetic drug Metformin works by activating this pathway to prevent cancer. The study provides new insights into the mechanism behind Metformin's tumor-suppressive action.
A recent study found that metformin treatment inhibits abnormal mitochondrial metabolism and activates anti-proliferation signaling in individuals with Li-Fraumeni syndrome. This inhibition leads to lower rates of tumor formation and increased survival time, suggesting metformin as a potential strategy for cancer prevention.
A new study from UT Southwestern Medical Center found that proactive outreach to cirrhosis patients doubled their screening rates for liver cancer. The study successfully improved early detection and survival rates among those at highest risk of adverse outcomes. Only one-fourth of cirrhosis patients are currently screened every six mo...
Researchers investigated resistance to antiangiogenic therapies using animal models, finding inconsistent definitions of treatment failure. The study emphasizes the need for improved methodology to accurately predict alternative strategies that benefit patients.
The largest genomic tumor profiling effort showed that large-scale clinical application of the methods is technically feasible, but faces significant challenges and unanswered questions. The study found that at least one actionable mutation was discovered in about two-thirds of patient samples, which could inform treatment decisions.
George Washington University researchers received a $2.2 million grant from the National Cancer Institute to investigate the role of human endogenous retroviruses (HERVs) in cancer development. They plan to use a novel computational pathway program, Telescope, to pinpoint HERV expression in various cancers.
Researchers have developed a new cancer treatment called photoimmunotherapy that combines the immune system with laser energy to target and destroy cancer cells. This innovative technique delivers precise, lethal payloads with minimal collateral damage.
Researchers at Texas A&M University found that breast cancer cells may evade treatment by consuming stem cells from bone marrow, making them difficult to kill. This mechanism could explain cancer recurrence and lead to new treatments, such as delivering toxic agents directly to cancer cells using stem cells as a delivery vehicle.
Researchers at Dana-Farber Cancer Institute found that cabozantinib exceeded sunitinib in progression-free survival and overall response rates for patients with metastatic kidney cancer. The study showed a 20% lower risk of death associated with cabozantinib treatment.
Researchers created a new cancer drug using gold nanoparticles to deliver paclitaxel directly to tumors, increasing effectiveness while reducing devastating side effects such as hair loss and nerve pain. Early lab tests showed the therapy to be nearly as effective as a high dose of paclitaxel alone.
Researchers at the University of Hawaii Cancer Center identified a protein called RSK2 as a driver of tumor cell invasion in glioblastoma. Inhibiting RSK2 stops the invasion and enhances chemotherapy effectiveness, offering new hope for patients with this aggressive brain cancer.
Research finds that tumor necrosis factor inhibitors used to treat juvenile idiopathic arthritis do not increase the risk of malignancy. The study, which analyzed data from over 27,000 children with JIA, concluded that TNFi are not associated with a significantly increased risk of incident malignancy.
Lung cancer is expected to result in an estimated 158,080 deaths in 2016 due to limited treatment options. Researchers are exploring signals within lung cancer cells that cause them to grow quickly and spread to other organs like the liver.
Researchers at Moffitt Cancer Center have developed a novel approach using mathematical modeling to accurately predict patient responses to cancer drugs in virtual clinical trials. This approach enables the identification of optimal treatment schedules that improve outcomes and reduce toxicities for melanoma patients.
A new study raises concerns about the effectiveness of expensive new cancer drugs in improving survival rates, citing limitations in clinical trials and high costs. Experts call for stricter approval criteria and improved patient consent processes to ensure fair and equitable treatment.
RK-33 reduces prostate cancer cell proliferation and increases sensitivity to radiation, offering a promising combination treatment for prostate cancer. The experimental drug has been shown to be effective in both laboratory cultures and animal models.
Researchers at Queen's University Belfast have identified a way to bypass bowel cancer's defence against the drug cetuximab by blocking the ADAM17 protein. This breakthrough could lead to a new combination therapy that delays or prevents cancer recurrence, improving patient outcomes.
An international team has developed a new method to analyze RNA structures linked to cancer. The research aims at understanding how four-stranded RNA structures called G-quadruplexes affect cellular processes such as RNA splicing, which is essential for producing proteins.
A new synthetic binding protein called NS1 monobody has been developed to block the activity of genetic mutations found in nearly 90% of pancreatic cancers. This breakthrough discovery provides insight into how RAS proteins function in cells, potentially leading to new therapeutic approaches for treating cancer.
Researchers use gold nanoparticles with radioactive tracers to target cancer cells' telomeres, shutting down telomerase and halting growth. The method holds promise for delivering a lethal payload to cancer cells, improving treatment outcomes.
The Lancet Commission estimates the monthly cost of a basic package of 201 essential medicines could be as low as $1-2 per person, addressing universal health coverage goals. However, many countries spend less than this amount on medicines, highlighting the need for additional financing to meet basic healthcare needs.
A new study from Massachusetts General Hospital finds that cigarette smoking significantly reduces the lifespan of people living with HIV in the U.S., potentially even more than HIV itself. Quitting smoking can greatly increase lifespan and is never too late to quit.
Researchers at Georgetown University Medical Center have developed a method to study cancer cell invasion and metastasis in real-time using zebrafish embryos. This approach allows for faster analysis of cancer questions, potentially leading to new treatments.
The SWOG and The Hope Foundation's efforts are paying off, with 13 NCTN trials now open to veterans at participating medical centers. Veterans like Jerry Valentino have successfully enrolled in trials, responding well to cutting-edge treatments.
A study published in The New England Journal of Medicine details two cases of acute and unexpected fatal myocarditis that occurred in melanoma patients following treatment with a combination of ipilimumab and nivolumab. High-dose corticosteroids were initially administered, but both patients died due to the severe immune reaction.
Researchers at The Wistar Institute have developed a combination therapy that improves chemoresistance in ovarian cancer. BET inhibitors can suppress ALDH activity, making treatment more effective when used with cisplatin. This approach has shown extended survival rates and delayed tumor growth in mice.
Researchers found that high levels of Manganese Superoxide Dismutase (MnSOD) trigger aggressive breast cancer cell behavior. By targeting MnSOD, scientists hope to develop effective therapeutic strategies against triple-negative breast cancer.
A new study identifies the Hedgehog signaling pathway as a central driver of gastrointestinal stromal tumors (GIST), which are often resistant to current treatments. Researchers have found that targeting this pathway with arsenic may offer a new approach to treatment, potentially killing multidrug-resistant cell lines.
A recent study found that hybrid structures composed of DNA and RNA play a crucial role in restoring genetic information after damage. The research also revealed that RNase H enzymes targeting these hybrids are vital for efficient DNA repair. This discovery offers potential for developing new cancer drugs targeting these enzymes.
The article explores the economic aspects of cancer care, highlighting the need to assess the value of healthcare innovation. It discusses the rising costs of new treatments and the potential impact on healthcare budgets. The Special Issue provides a review of health economics in cancer research and care.
Researchers at Boston University School of Medicine have discovered a potential treatment option for ovarian cancer by combining calpeptin with epigenetic inhibitors. The therapy shows promise in killing cancer cells and preventing their growth, offering new hope for women affected by the disease.
A new Penn Medicine study fails to find NLR reliable for predicting cancer progression and treatment response in bladder cancer patients. The researchers analyzed data from a prospective clinical trial, which showed that NLR was not effective as a prognostic or predictive biomarker.
Researchers developed a way to attach labels to cancer drugs packaged in liposomes, allowing for imaging with PET to see where they accumulate in the body. This method shows promise in predicting drug delivery to cancer tissues in specific patients, potentially leading to more effective treatments and reduced side effects.
A recent study published in JAMA Internal Medicine estimates that nearly 40% of cancer deaths in men are linked to smoking, with the South experiencing the highest rates. The research suggests that weaker tobacco control policies and lower socioeconomic status contribute to these disparities.
Researchers at Aarhus University combined two scanning technologies to create high-resolution images of cancer tumors in mice, providing detailed mapping of blood vessels. This method could lead to the development of more effective drugs and personalized treatment plans.
Researchers use fission yeast to discover new cancer drugs targeting active proteins involved in DNA replication. The unique "arched and snapped" appearance of treated cells suggests potential for accelerating drug development.
Researchers at MUSC Hollings Cancer Center discover a mechanism conferring resistance to AML drugs and develop a ceramide-based therapeutic that reactivates mitophagy, killing drug-resistant cancer cells. The treatment has clinical appeal due to its specificity towards cancer cells.
Scientists at TUM have discovered new mechanisms of action for Imiquimod, a medication used to treat viral skin infections and certain types of skin cancer. The study reveals that Imiquimod activates the NLRP3 inflammasome, which can lead to inflammation and potentially contribute to its efficacy or adverse side effects.
A new compound, S63845, has been shown to block a protein essential for the sustained growth of up to a quarter of all cancers. This research holds promise for treating blood and solid cancers, including acute myeloid leukaemia and melanoma.
Researchers at Johns Hopkins Medicine have developed a modified cancer drug that enhances its ability to reach the brain, improving delivery and reducing toxicity. The new compound shows promise in treating brain tumors by targeting tumor metabolism and evading immune cells.
Rural Appalachia faces alarming disparities in cancer care, including higher mortality rates, late diagnoses, and limited access to comprehensive treatment. The region has seen a decline in cancer incidence nationwide, but its cancer death rate has increased, with rural residents facing significantly worse outcomes.
Researchers at USC Fertility found modified natural cycle IVF to be a cost-effective fertility method, saving up to $7,000 per live birth compared to conventional IVF. This approach takes less time and is gentler on the body, making it more accessible to younger patients.
Eleven cancers causing most loss of healthy life years in the US are closely associated with preventable risk factors like smoking and alcohol. Lung cancer accounts for 24% of the burden, followed by breast, colorectal, pancreatic, prostate, leukemia, liver, brain, non-Hodgkin lymphoma, and ovarian cancers.
Researchers develop artificial cell-like spheres from natural proteins to study drug transport and variability. Variants in genes ABCB1 and CYP19A1 associated with anastrozole concentrations and joint pain in breast cancer patients.
Researchers at Weill Cornell Medicine found that chemotherapy kills urothelial cancer cells but shapes their genetic evolution, leading to drug-resistant cell clones. This study provides a framework for understanding the biological basis of chemotherapy resistance in bladder cancer and may lead to improved diagnostics and treatments.
Researchers at Hokkaido University discovered that a nonsteroid anti-inflammatory drug used for treating colds can suppress the spread of bladder cancers and reduce chemoresistance in mice. The study identified the metabolic enzyme aldo-keto reductase 1C1 (AKR1C1) as a key player in cancer progression.
A recent scandal in Brazil highlights the dangers of unproven compounds being sold to cancer patients. The authors argue that skipping clinical research phases puts patients at risk of false hopes and dangerous treatments. They emphasize the need for evidence-based medicine and the importance of testing novel drug candidates.
Researchers from the Repurposing Drugs in Oncology project found that propranolol has significant anti-cancer properties, particularly in angiosarcoma. The study highlights the potential of propranolol to act on multiple points of the metastatic cascade, reducing metastatic spread and saving lives.
Changes in protein modifications generate biological diversity needed for evolution, allowing species to adapt to environments. Most phosphorylation sites arose relatively recently in evolution, contributing significantly to evolutionary diversity and highlighting potential avenues for therapeutic research.
A team of researchers at the Salk Institute has found a way to obstruct the creation of fat molecules in cancer cells, stalling their growth. This approach involves inhibiting an enzyme called Acetyl-CoA Carboxylase, which is crucial for lipid synthesis activity.
Researchers aim to learn about physical parameters limiting drug delivery into brain tumors to improve treatment selection for unique tumors.
A team of international scientists has outlined 14 recommendations to improve the adoption of new cancer scans in clinics. The guidelines aim to address challenges such as variability in methodologies and lack of reproducibility across laboratories.
Scientists at Harvard's Wyss Institute have developed a way to analyze the effect of mechanical stiffness on chemotherapy treatment. The new method uses alginate hydrogels to mimic tumor and normal tissue environments, revealing that softer matrix conditions lead to increased resistance.
A new study suggests that combining an experimental PARP inhibitor with an epigenetic drug can strengthen treatment effectiveness against breast cancer cells without BRCA mutations, as well as leukemia cells. The combination therapy resulted in a strong antitumor response and halted tumor growth.
Researchers discovered a novel mechanism in a combination drug therapy that disrupts cancer cells' ability to survive DNA damage. The therapy combines DNA methyltransferase inhibitors with poly-ADP-ribose polymerase inhibitors, causing massive DNA damage that leads to cancer cell death.
Researchers at MIT and Dana-Farber Cancer Institute developed a novel way to test tumors for drug susceptibility using a device that measures single-cell masses. They successfully tested this approach with glioblastoma and acute lymphocytic leukemia, finding that susceptible cells reduce growth rates while resistant cells continue unaf...